After reading the following paragraph, answer the question (s) below. As a scientist employed by the FDA, you've been asked to sit on a panel to evaluate a pharmaceutical company's application for approval of a new weight loss drug called Fat Away. The company has submitted a report summarizing the results of their animal and human testing. In the report, it was noted that Fat Away works by affecting the electron transport chain. It decreases the synthesis of ATP by making the mitochondrial membrane permeable to H + which allows H + to leak from the mitochondrial matrix to the intermembrane space. This effect leads to weight loss. Fat Away prevents ATP from being made by:

By preventing the binding of ADP and Inoganic phosphate to the catalytic part ot ATP synthase.

Explanation:

The ATP synthase its a enzyme complex located at the membrane of mitochondria, that transforms ADP to ATP. To perform this reaction the ATP synthase, needs a gradient of H+. This gradient of H + is made during electron transport chain. Once the gradient of H + its made, the H + passes through the ATP synthase and performs a conformational change to the enzymatic complex. This conformational change enables the catalytic part of the ATP synthase to be exposed, so that it can bind ADP and inorganic phosphate. After this substrates bind, a chemical reaction is performed between ADP and inorganic phosphate. The products of this reaction are ATP and water. Since Fat Away makes mitochondrial membrane permeable to H+, no gradient of H + is established, and H + can not pass through the ATP synthase. So no conformational change is made to the ATP synthase, and the catalytic part of the ezyme cant bind ADP and inorganic phosphate, to perform the synthesis of ATP.